Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain

A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcal pneumonia (NBP) and invasive pneumococcal disease (IPD).

Detalles Bibliográficos
Autores: Cantarero, David, Ocaña, Daniel, Onieva-García, María Ángeles, Rodríguez-García, Juan, Gálvez, Paulina, Méndez, Cristina, Crespo Palomo, Carlos, López-Ibáñez de Aldecoa, Alejandra
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2023
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/218975
Acceso en línea:https://hdl.handle.net/2445/218975
Access Level:acceso abierto
Palabra clave:Vacuna antipneumocòccica
Anàlisi cost-benefici
Pneumococcal vaccine
Cost effectiveness
Descripción
Sumario:A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcal pneumonia (NBP) and invasive pneumococcal disease (IPD).

Similares en LA Referencia